Repeated porphyrin lipoprotein‐based photodynamic therapy controls distant disease in mouse mesothelioma via the abscopal effect

Authors:

Abstract
While photodynamic therapy (PDT) can induce acute inflammation in the irradiated tumor site, a sustained systemic, adaptive immune response is desirable, as it may control the growth of nonirradiated distant disease. Previously, we developed porphyrin lipoprotein (PLP), a ∼20 nm nanoparticle photosensitizer, and observed that it not only efficiently eradicated irradiated primary VX2 buccal carcinomas in rabbits, but also induced regression of nonirradiated metastases in a draining lymph node. We hypothesized that PLP‐mediated PDT can induce an abscopal effect and we sought to investigate the immune mechanism underlying such a response in a highly aggressive, dual subcutaneous AE17‐OVA+ mesothelioma model in C57BL/6 mice. Four cycles of PLP‐mediated PDT was sufficient to delay the growth of a distal, nonirradiated tumor four‐fold relative to controls. Serum cytokine analysis revealed high interleukin‐6 levels, showing a 30‐fold increase relative to phosphate‐buffered solution (PBS) treated mice. Flow cytometry revealed an increase in CD4+ T cells and effector memory CD8+ T cells in non‐irradiated tumors. Notably, PDT in combination with PD‐1 antibody therapy prolonged survival compared to monotherapy and PBS. PLP‐mediated PDT shows promise in generating a systemic immune response that can complement other treatments, improving prognoses for patients with metastatic cancers.
Funding Information
  • Princess Margaret Cancer Foundation
  • Natural Sciences and Engineering Research Council of Canada (Grant Number 386613)

This publication has 37 references indexed in Scilit: